Effect of low dose Semaglutide in people with Type 1 Diabetes and excess weight

Bruno A Grassi; María Teresa Onetto; Camila Sánchez; Nicole Tapia; Francisca Mena

doi:10.1016/j.diabres.2024.111593

Effect of low dose Semaglutide in people with Type 1 Diabetes and excess weight

Diabetes Res Clin Pract. 2024 Mar:209:111593. doi: 10.1016/j.diabres.2024.111593. Epub 2024 Feb 24.

Authors

Bruno A Grassi¹, María Teresa Onetto², Camila Sánchez², Nicole Tapia², Francisca Mena²

Affiliations

¹ Departamento de Nutrición, Diabetes y Metabolismo, Escuela de Medicina, Facultad de Medicina, Pontificia Universidad Católica de Chile, Diagonal Paraguay 362, Santiago, Chile. Electronic address: bagrassi@gmail.com.
² Departamento de Nutrición, Diabetes y Metabolismo, Escuela de Medicina, Facultad de Medicina, Pontificia Universidad Católica de Chile, Diagonal Paraguay 362, Santiago, Chile.

PMID: 38403174
DOI: 10.1016/j.diabres.2024.111593

Abstract

Obesity is a prevalent problem in people living with T1D (PwT1D), and it has been linked to cardiovascular disease in this population. The use of low dose weekly Semaglutide (0,5 mg) was evaluated in a cohort of PwT1D and excess weight.

Keywords: GLP-1 receptor agonists; Obesity; Type 1 Diabetes.

MeSH terms

Diabetes Mellitus, Type 1* / drug therapy
Diabetes Mellitus, Type 2* / epidemiology
Glucagon-Like Peptide-1 Receptor
Glucagon-Like Peptides / therapeutic use
Humans
Hypoglycemic Agents / therapeutic use
Weight Gain

Substances

Hypoglycemic Agents
semaglutide
Glucagon-Like Peptides
Glucagon-Like Peptide-1 Receptor